Last Update 05 Aug 26
Fair value Increased 10%CAS: Containerboard Pricing Upside And Tissue Investment Will Test Earnings Trajectory
The analyst price target for Cascades has shifted higher from CA$13.33 to CA$14.67, reflecting recent Street research in which firms raised their targets into the CA$15 to CA$19 range, as analysts point to improved containerboard pricing and unmodeled upside to EBITDA guidance.
Analyst Commentary
Recent research on Cascades highlights a clear shift in sentiment, with several firms adjusting ratings and targets as they reassess containerboard pricing and earnings potential. The latest calls focus on how current guidance lines up with the new pricing backdrop and what that might mean for valuation and execution risk.
Bullish Takeaways
- Bullish analysts see the move in price targets to the C$15 to C$19 range as a reset that better reflects current containerboard pricing and potential EBITDA that is not fully captured in existing guidance.
- The upgrade to an Outperformer rating with a C$15 target is framed around improved containerboard pricing, which these analysts view as a support for stronger earnings power at Cascades.
- Bullish analysts highlight the recent US$50 per ton containerboard price move, which they say was not included in the company’s EBITDA guidance and could represent additional upside if realized in results.
- Successive price target increases from C$13 to C$13.50, then to C$16 and C$19, are seen as evidence that these analysts are gaining confidence in Cascades’ ability to execute on its plan under the updated pricing environment.
Bearish Takeaways
- Bearish analysts previously cut targets by C$1 to C$1.50, which signals earlier concern around earnings visibility and execution risk before the recent turn in containerboard pricing.
- Those earlier target reductions suggest some investors may still focus on the possibility that operational or cost pressures could limit how much of the pricing backdrop flows through to Cascades’ EBITDA.
- The existence of both prior cuts and later increases in targets indicates that conviction is not uniform, and that valuation for Cascades still depends heavily on how quickly and fully pricing moves show up in reported results.
- Some cautious views may center on the risk that current targets in the mid to high teens could leave less room for error if EBITDA does not track toward the upside that bullish analysts expect from unmodeled pricing benefits.
What’s in the News for Cascades
- Cascades plans to install a new tissue converting line at its Granby, Quebec facility, a C$15 million investment over 9 months that follows a prior C$14 million spend, for a total of C$29 million in recent investments. Source, Company key developments.
- The new Granby line is expected to have capacity of 3 million cases and is scheduled to begin production in the fourth quarter of 2026, which management indicates is intended to better meet customer needs. Source, Company key developments.
- Cascades states that the Granby investment is expected to help secure 239 jobs at the plant and support skills development in the Haute Yamaska region. Source, Company key developments.
- For the first quarter ended March 31, 2026, Cascades reported impairment charges of C$8 million on a building and equipment tied to a previously closed United States plant, affecting operating income and net earnings. Source, Company key developments.
Valuation Changes for Cascades
- Fair Value was CA$13.33 in the prior framework and is now CA$14.67, indicating a higher central estimate for Cascades under the updated assumptions.
- The Discount Rate moved from 8.06% to 7.65%, which points to a slightly lower required return being used in the new valuation work.
- Revenue Growth was previously set at 22.78% and is now shown as 343.71%, which is a very large change in the growth input applied to CA$ revenue in the updated model.
- The Net Profit Margin was adjusted from 16.29% to 513.41%, indicating a very large shift in the assumed profitability for Cascades in the revised estimates.
- The Future P/E moved from 2.18x to 6.85x, which reflects a higher valuation multiple being applied to Cascades in the updated analysis.
Catalysts
About Cascades
Cascades manufactures packaging and tissue products with a focus on cost efficiency and sustainable fiber sourcing.
What are the underlying business or industry changes driving this perspective?
- Continued ramp up at the Bear Island mill toward Greenpac level efficiencies, combined with targeted reductions in chemical and material usage, should lift Packaging segment productivity and support structurally higher EBITDA margins.
- Ongoing profitability initiatives, already contributing roughly $10 million sequentially and targeting a $100 million run rate uplift by the end of 2026, position the company to expand earnings even in a flat demand environment through lower unit operating costs.
- Industry wide focus on recycled content and domestic OCC utilization, alongside Cascades’ disciplined sourcing and quality tracking, should sustain favorable input spreads over time and bolster gross margins as recovered fiber markets rebalance.
- Portfolio optimization through plant closures and asset monetization of up to $120 million by mid 2026, followed by redeployment of capital into higher return mills, is expected to reduce leverage toward 2.5 to 3 times and lower financing expense, supporting net earnings growth.
- Strengthening tissue volumes in both retail and away from home channels, supported by recent investments at Kingsey Falls, Granby and the Pryor mill, should drive higher sales and better mix, improving segment level EBITDA and consolidated revenue resilience.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Cascades's revenue will grow by 3.4% annually over the next 3 years.
- Analysts assume that profit margins will increase from 2.1% today to 5.1% in 3 years time.
- Analysts expect earnings to reach CA$269.7 million (and earnings per share of CA$2.63) by about August 2029, up from CA$102.0 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 6.9x on those 2029 earnings, down from 14.1x today. This future PE is lower than the current PE for the CA Packaging industry at 13.4x.
- Analysts expect the number of shares outstanding to grow by 0.06% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.65%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Macroeconomic uncertainty and pressure on North American consumers, especially around key retail periods such as post-Thanksgiving and Christmas, could weaken box shipments and tissue demand more than expected, leading to lower volumes and softer revenue growth over the medium term.
- If recovered fiber availability declines due to lower OCC generation and reduced recycling activity while quality also deteriorates, Cascades could face rising input costs that erode the current benefit from favorable raw material trends and compress gross margins and EBITDA.
- Should the Bear Island mill and other operational excellence initiatives fail to fully achieve targeted efficiency and cost savings, or take longer than the 6 to 24 month window management is planning, the company may not reach its profitability improvement objective of 100 million by 2026, limiting the forecast expansion in EBITDA and net earnings.
- Plant closures, environmental provisions and restructuring charges, such as those related to Niagara Falls and the 2024 Canadian facility, highlight ongoing portfolio rationalization that could expose the company to additional one-time costs or lost contribution from divested assets, which would weigh on net income even as operating performance improves.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of CA$14.67 for Cascades based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CA$19.0, and the most bearish reporting a price target of just CA$13.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CA$5.3 billion, earnings will come to CA$269.7 million, and it would be trading on a PE ratio of 6.9x, assuming you use a discount rate of 7.7%.
- Given the current share price of CA$14.16, the analyst price target of CA$14.67 is 3.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Cascades?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
